Victoza

Product manufactured by Novo Nordisk

Application Nr Approved Date Route Status External Links
NDA022341 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Victoza Is Indicated: • As An Adjunct To Diet And Exercise To Improve Glycemic Control In Patients 10 Years And Older With Type 2 Diabetes Mellitus, • To Reduce The Risk Of Major Adverse Cardiovascular Events (cardiovascular Death, Non-Fatal Myocardial Infarction, Or Non-Fatal Stroke) In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease [see Clinical Studies (14.3) ] . Limitations Of Use : • Victoza Should Not Be Used In Patients With Type 1 Diabetes Mellitus Or For The Treatment Of Diabetic Ketoacidosis, As It Would Not Be Effective In These Settings. • The Concurrent Use Of Victoza And Prandial Insulin Has Not Been Studied. Victoza Is A Glucagon-Like Peptide-1 (glp-1) Receptor Agonist Indicated: • As An Adjunct To Diet And Exercise To Improve Glycemic Control In Patients 10 Years And Older With Type 2 Diabetes Mellitus (1) . • To Reduce The Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease ( 1 ). Limitations Of Use : • Not For Treatment Of Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis. • Has Not Been Studied In Combination With Prandial Insulin.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Liraglutide

Comments